Recon
The reagent within the enhanced BreathScan® tube is based on Akers Biosciences, Inc. (ABI) proprietary Micro Particle Catalyzed (MPC) Biosensor technology, which permits precise, rapid identification of a wide range of medical conditions through biomarkers in breath condensate.
The reactive micro particles are packaged into an ampoule in the tube, which is crushed immediately prior to use, releasing the particles. Through a catalyzed process, these reactive particles form a complex with a biomarker in the breath condensate which is then viewed as a colour change.
In the BreathScan PRO operating system the reagent is formulated to react to ethyl alcohol in the breath condensate which is analysed using proprietary technology to deliver a precise result of % BAC.
Akers Biosciences, Inc.: BreathScan Innovator
Designer, manufacturer and distributor of rapid diagnostic screening and testing products, ABI is an In Vitro Diagnostic (IVD) device specialist and a key partner in BreathScan programme and product delivery.
Evolving from traditional laboratories, diagnostic tests are now increasingly performed at or near Point of Care.
ABI’s propietary platform technologies provide physicians, safety professionals, consumers and a variety of other stakeholders with immediate, accurate test results to facilitate the real-time assessment of an individual’s health status.
ABI’s patented breath condensate collection technology also forms the basis of the Company’s expanding product portfolio that will include rapid, disposable screening tests for breath ketone, asthma, Chronic Obstructive Pulmonary Disease (COPD) and lung cancer.
